- Project status
- Laura Shallcross
- Host institution
- University College London
- Team members
- Maria Krutikov, Tom Palmer, Gokhan Tut, Chris Fuller, Madhumita Shrotri, Haydn Williams, Daniel Davies, Aidan Irwin-Singer, James Robson, Andrew Hayward, Paul Moss, Andrew Copas, Laura Shallcross, Rebecca Giddings, Borscha Azmi, Rachel Bruton
- Funding information (if funded)
- Department of Health and Social Care
- Project Summary
The VIVALDI study, investigates the epidemiology of SARS-CoV2 infection amongst care home residents and staff in England, through collaboration with a range of Care Home Providers.
We will undertake a cohort study collecting serial blood samples from staff and residents in c.200 care-homes in England. Blood results will be linked to results from nasopharyngeal PCR swab testing undertaken through the national testing programme. Results of nasopharyngeal PCR testing will also be collected from a further >100 homes where blood samples were not collected. Data collection began in June 2020 and will end in April 2022.
The data will be used to investigate the proportion of staff and residents who become infected with SARS-CoV-2, the duration of the antibody response and the vaccine-induced immune response.
Data linkage with hospital episode statistics and mortality data will provide insight into outcomes and transmission amongst staff and residents. Linkage of PCR testing data with information on hospital admissions, and analysis of viral sequencing will provide insights into:
• the patterns of disease transmission within care homes,
• the role of high-risk groups,
• how often infection is either imported from or exported to care home settings from the community or hospitals.
This work will provide robust data to inform optimal approaches for SARS-CoV2 control and prevention within care homes. Individual level-data will be made available to individuals involved in provision of direct care to residents. Aggregate data outputs (at regional and national level will be made widely available.
• To estimate the proportion of care home staff and residents who have been infected with SARS-CoV-2 and investigate how this varies by care home characteristics and individual-level characteristics.
• To monitor vaccine effectiveness against laboratory-confirmed SARS-CoV-2 in care home staff and residents, and outbreaks
- Outputs / Expected Outputs
Shroti M, et al (2021). Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study) doi: https://doi.org/10.1101/2021.03.26.21254391 medRxiv preprint
Krutikov, M et al. (2021). Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. Lancet Healthy Longev 2021; 2: e362–70 https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00093-3/fulltext
- United Kingdom
- Care setting
- Care homes/LTC facilities
- Funding type
- COVID-19 Infection rates | Deaths | Improved care home design
- Intervention types
- Digital records/data linkage | Vaccination
- Other | Secondary data analysis
- Care provider/care organisations | People living in care homes | Staff working in long-term care